Literature DB >> 11861857

Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product.

Stéphanie Mercier1, Hanne Gahéry-Segard, Martine Monteil, Renée Lengagne, Jean-Gérard Guillet, Marc Eloit, Caroline Denesvre.   

Abstract

Adenovirus-mediated gene delivery via the intramuscular route efficiently promotes an immune response against the transgene product. In this study, a recombinant adenovirus vector encoding beta-galactosidase (Ad beta Gal) was used to transduce dendritic cells (DC), which are antigen-presenting cells, as well as myoblasts and endothelial cells (EC), neither of which present antigens. C57BL/6 mice received a single intramuscular injection of Ad beta Gal-transduced DC, EC, or myoblasts and were then monitored for anti-beta-galactosidase (anti-beta-Gal) antibody production, induction of gamma interferon-secreting CD8(+) T cells, and protection against melanoma tumor cells expressing beta-Gal. While all transduced cell types were able to elicit an antibody response against the transgene product, the specific isotypes were distinct, with exclusive production of immunoglobulin G2a (IgG2a) antibodies following injection of transduced DC and EC versus equivalent IgG1 and IgG2a responses in mice inoculated with transduced myoblasts. Transduced DC induced a strong ex vivo CD8(+) T-cell response at a level of 50% of the specific response obtained with the Ad beta Gal control. In contrast, this response was 6- to 10-fold-lower in animals injected with transduced myoblasts and EC. Accordingly, only animals injected with transduced DC were protected against a beta-Gal tumor challenge. Thus, in order to induce a strong and protective immune response to an adenovirus-encoded transgene product, it is necessary to transduce cells of dendritic lineage. Importantly, it will be advantageous to block the transduction of DC for adenovirus-based gene therapy strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861857      PMCID: PMC136003          DOI: 10.1128/jvi.76.6.2899-2911.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

Review 1.  Immunobiology of human vascular endothelium.

Authors:  J S Pober
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Macrophages and dendritic cells in normal and regenerating murine skeletal muscle.

Authors:  A Pimorady-Esfahani; M D Grounds; P G McMenamin
Journal:  Muscle Nerve       Date:  1997-02       Impact factor: 3.217

Review 3.  The expanding universe of T-cell subsets: Th1, Th2 and more.

Authors:  T R Mosmann; S Sad
Journal:  Immunol Today       Date:  1996-03

4.  Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells.

Authors:  Y Wan; P Emtage; Q Zhu; R Foley; A Pilon; B Roberts; J Gauldie
Journal:  Cell Immunol       Date:  1999-12-15       Impact factor: 4.868

5.  Histochemical staining following LacZ gene transfer underestimates transfection efficiency.

Authors:  T Couffinhal; M Kearney; A Sullivan; M Silver; Y Tsurumi; J M Isner
Journal:  Hum Gene Ther       Date:  1997-05-20       Impact factor: 5.695

6.  Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset.

Authors:  D Rea; F H Schagen; R C Hoeben; M Mehtali; M J Havenga; R E Toes; C J Melief; R Offringa
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo.

Authors:  Y Yang; K U Jooss; Q Su; H C Ertl; J M Wilson
Journal:  Gene Ther       Date:  1996-02       Impact factor: 5.250

8.  Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells.

Authors:  J B Ulmer; R R Deck; C M Dewitt; J I Donnhly; M A Liu
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

9.  Gene vaccination with naked plasmid DNA: mechanism of CTL priming.

Authors:  M Corr; D J Lee; D A Carson; H Tighe
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

10.  Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells.

Authors:  B Sauter; M L Albert; L Francisco; M Larsson; S Somersan; N Bhardwaj
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

View more
  17 in total

1.  miRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens.

Authors:  Matthias W Kron; Sigrid Espenlaub; Tatjana Engler; Reinhold Schirmbeck; Stefan Kochanek; Florian Kreppel
Journal:  Mol Ther       Date:  2011-05-10       Impact factor: 11.454

2.  Human parainfluenza virus type 2 vector induces dendritic cell maturation without viral RNA replication/transcription.

Authors:  Kenichiro Hara; Masayuki Fukumura; Junpei Ohtsuka; Mitsuo Kawano; Tetsuya Nosaka
Journal:  Hum Gene Ther       Date:  2013-07       Impact factor: 5.695

3.  Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors.

Authors:  Florian Kühnel; Bernd Schulte; Thomas Wirth; Norman Woller; Sonja Schäfers; Lars Zender; Michael Manns; Stefan Kubicka
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo.

Authors:  Chengwen Li; Matthew Hirsch; Aravind Asokan; Brian Zeithaml; Hong Ma; Tal Kafri; R Jude Samulski
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

5.  Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine.

Authors:  Anja Krause; Yaqin Xu; Sara Ross; Wendy Wu; Ju Joh; Stefan Worgall
Journal:  Virol J       Date:  2011-07-29       Impact factor: 4.099

6.  Gene Therapy Applications to Cancer Treatment.

Authors:  Susy M. Scholl; Silke Michaelis; Ray McDermott
Journal:  J Biomed Biotechnol       Date:  2003

Review 7.  Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.

Authors:  Lynda Coughlan
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

8.  Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection.

Authors:  Raveen Rathnasinghe; Shirin Strohmeier; Fatima Amanat; Virginia L Gillespie; Florian Krammer; Adolfo García-Sastre; Lynda Coughlan; Michael Schotsaert; Melissa B Uccellini
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

9.  Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model.

Authors:  Fatima Amanat; Shirin Strohmeier; Raveen Rathnasinghe; Michael Schotsaert; Lynda Coughlan; Adolfo García-Sastre; Florian Krammer
Journal:  mBio       Date:  2021-03-02       Impact factor: 7.867

10.  Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection.

Authors:  Raveen Rathnasinghe; Shirin Strohmeier; Fatima Amanat; Virginia L Gillespie; Florian Krammer; Adolfo García-Sastre; Lynda Coughlan; Michael Schotsaert; Melissa Uccellini
Journal:  bioRxiv       Date:  2020-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.